LifeSensors Attending the 5th Annual Targeted Protein Degradation Summit MALVERN, PA., AUG 30, 2022 -- LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, Molecular Glues, and neurodegeneration...
Read More
By: Rebekah Varghese, Derrick Padykula, & Jacob Huang All the FDA-approved drugs combined interact with only 2% of the proteins found in human cells, according to Dr. Brent Stockwell, a…
By: Rebekah Varghese and Derrick Padykula Parkinson’s Disease (PD) is the second most common neurodegenerative disease, affecting 1-2% of the population. Now, when you consider the world’s population to be…
The Ubiquitin-Proteasome System: An Overview The Ubiquitin-Proteasome system (UPS) is a highly complex, temporally controlled and conserved pathway that plays a major role in a myriad on cellular functions….
November is a month dedicated to the awareness of Alzheimer’s Disease, an age-related illness of the brain that causes cognitive and physiological decline. LifeSensors has great appreciation for our fellow…
DTE proteins, or ‘difficult-to-express’ proteins are a common hurdle for researchers in the lab. Due to difficulty with correct protein folding and general protein synthesis success, coronavirus proteins find themselves…
LifeSensors is happy to say we’re growing! We’ve always been one to say more the merrier, and now we truly are. With Axxora, we can offer near-complete global availability to...
Read More
FDA Provisional Approval LifeSensors is proud to announce its provisional FDA approval for our COVID-19 IgG ELISA Detection Kit to address the critical need for COVID-19 diagnostics through serological testing….